Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Cilgavimab/tixagevimab/remdesivir

Myocardial infarction, sinus bradycardia and off label use: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Mikulska M, et al. Triple Combination Therapy with 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clinical Infectious Diseases 77: 280-286, No. 2, 15 Jul 2023. Available from: URL: http://doi.org/10.1093/cid/ciad181 Mikulska M, et al. Triple Combination Therapy with 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clinical Infectious Diseases 77: 280-286, No. 2, 15 Jul 2023. Available from: URL: http://​doi.​org/​10.​1093/​cid/​ciad181
Metadaten
Titel
Cilgavimab/tixagevimab/remdesivir
Myocardial infarction, sinus bradycardia and off label use: 2 case reports
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47849-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

COVID-19-vaccine

Case report

Rituximab

Case report

Etanercept

Case report

Multiple drugs

Case report

Infliximab

Case report

Amiodarone